Clinical cases of Pseudomonas aeruginosa eradication in patients with cystic fibrosis

Pseudomonas aeruginosa is the most common highly pathogenic flora in patients with cystic fibrosis. It is associated with severe lung damage and affects life expectancy. According to the register of patients with cystic fibrosis in the Russian Federation (2019), the incidence of P. aeruginosa pulmonary infection among them is 34.3%. Inhaled tobramycin is the drug of choice for the eradication of P. aeruginosa in patients with cystic fibrosis according to European and Russian recommendations. Clinical studies showed that Bramitob is highly effective against P. aeruginosa infection in patients with cystic fibrosis.

The aim of the study: to demonstrate the effectiveness and safety of eradication therapy with inhaled tobramycin in several clinical cases of children with cystic fibrosis.

Methods. The article analyzes 6 clinical cases of effective eradication of P. aeruginosa in patients with cystic fibrosis, including 1 clinical case that involved a new approach to assessing the resistance of P. aeruginosa. Positive culture of P. aeruginosa was confirmed in all patients in specialized laboratories (State Budgetary Healthcare Institution “Morozov Children’s City Clinical Hospital of the Department of Health of the City of Moscow”, Federal State Budgetary Institution “N.F.Gamaleya National Research Center for Epidemiology and Microbiology”, Ministry of Health of the Russian Federation). All patients received inhaled tobramycin 300 mg 2 times a day for 1 – 3 courses (a course of 28 days of inhalations/28 days – a break).

Results. All children tolerated tobramycin well, and two of them were younger than 6 years old. The effectiveness of eradication was confirmed by negative cultures of P. aeruginosa during 1-year follow-up that included quarterly microbiological control. The clinical case that involved assessment of resistance to inhaled tobramycin is especially important because of polyresistance of the pathogen.

Conclusion. The presented clinical cases of eradication of P. aeruginosa with the use of tobramycin confirm its clinical efficacy and wider application possibilities.

1. Kondrat’eva E.I., Kashirskaya N.Yu., Kapranov N.I., eds. [National consensus. Cystic fibrosis: definition, diagnostic criteria, therapy]. Moscow; 2016. Available at: https://mukoviscidoz.org/doc/konsensus/CF_consensus_2017.pdf (in Russian).

2. Kapranov N.I., Kashirskaja N.Ju., eds. [Cystic fibrosis]. Moscow: Medpraktika-M; 2014 (in Russian).

3. Zemanick E.T., Wagner B.D., Robertson C.E. et al. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann. Am. Thorac. Soc. 2015; 12 (2): 221–229. DOI: 10.1513/AnnalsATS.201407-310OC.

4. Bene Z., Fejes Z., Macek M. Jr. et al. Laboratory biomarkers for lung disease severity and progression in cystic fibrosis. Clin. Chim. Acta. 2020; 508: 277–286. DOI: 10.1016/j.cca.2020.05.015.

5. Elborn J.S. Cystic fibrosis. Lancet. 2016; 388 (10059): 2519–2531. DOI: 10.1016/s0140-6736(16)00576-6.

6. Goss C.H., Burns J.L. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007; 62 (4): 360–367. DOI: 10.1136/thx.2006.060889.

7. Kashirskoy N.Yu., Kondrat’evoy E.I., Krasovskogo S.A. et al., eds. [Register of patients with cystic fibrosis in the Russian Federation. 2019 year]. Moscow: MEDPRAKTIKA-M, 2021. Available at: https://mukoviscidoz.org/doc/registr/site_Registre_2019.pdf (in Russian).

8. Lazareva A.V., Chebotar’ I.V., Kryzhanovskaya O.A. et al. [Pseudomonas aeruginosa: pathogenicity, pathogenesis and pathology]. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2015; 17 (3): 170–186. Available at: https://cyberleninka.ru/article/n/pseudomonas-aeruginosa-patogennost-patogenez-i-patologiya (in Russian).

9. ECFS patient registry annual data report. 2017. Available at: https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report2017_v1.3.pdf

10. Somayaji R., Parkins M.D., Shah A. et al. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J. Cyst. Fibros. 2019; 18 (2): 236–243. DOI: 10.1016/j.jcf.2019.01.008.

11. Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fi osi. Cochrane Database Syst. Rev. 2014; (11): CD004197. DOI: 10.1002/14651858.CD004197.pub4.

12. Pressler T., Bohmova C., Conway S. et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J. Cyst. Fibros. 2011; 10 (Suppl. 2): S75–88. DOI: 10.1016/S1569-1993(11)60011-8.

13. Ho S.A., Lee T.W., Denton M. et al. Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J. Cyst. Fibros. 2009; 8 (1): 43–46. DOI: 10.1016/j.jcf.2008.08.001.

14. Morton R., Doe S., Banya W. et al. Clinical benefit of continuous nebulised Aztreonam Lysine for Inhalation (AZLI) in adults with cystic fibrosis – a retrospective cohort study. J. Cyst. Fibros. 2017; 16 (Suppl. 1): S55.

15. Smyth A.R., Bell S.C., Bojcin S. et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J. Cyst. Fibros. 2014; 13 (Suppl. 1): S23–42. DOI: 10.1016/j.jcf.2014.03.010.

16. Castellani C., Duff A.J.A., Bell S.C. et al. ECFS best practice guidelines: the 2018 revision. J. Cyst. Fibros. 2018; 17 (2): 153–178. DOI: 10.1016/j.jcf.2018.02.006.

17. Ratjen F., Munck A., Kho P. et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010; 65 (4): 286–291. DOI: 10.1136/thx.2009.121657.

18. Taccetti G., Bianchini E., Cariani L. et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomized multicentre study comparing two different protocols. Thorax. 2012; 67 (10): 853–859. DOI: 10.1136/thorax-jnl-2011-200832.

19. Proesmans M., Vermeulen F., Boulanger L. et al. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J. Cyst. Fibros. 2013; 12 (1): 29–34. DOI: 10.1016/j.jcf.2012.06.001.

20. Döring G., Flume P., Heijerman H. et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012; 11 (6): 461–479. DOI: 10.1016/j.jcf.2012.06.001

21. Lillquist Y.P., Cho E., Davidson A.G. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs 2009. J. Cyst. Fibrosis. 2011; 10 (3): 175–180. DOI: 10.1016/j.jcf.2011.01.002.

22. Ratjen F., Doring G., Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet. 2001; 358 (9286): 983–984. DOI: 10.1016/s0140-6736(01)06124-4.

23. Gibson R.L., Emerson J., McNamara S. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167 (6): 841–849. DOI: 10.1164/rccm.200208-855oc.

24. Ministry of Health of the Russian Federation. [Cystic fibrosis: clinical guidelines]. 2021. Available at: http://disuria.ru/_ld/11/1113_kr21E84MZ.pdf (in Russian).

25. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6 (Suppl. 16): 5–40. DOI: 10.1183/09041950.005s1693.

26. Poole K., Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr. Top. Med. Chem. 2001; 1 (1): 59–71. DOI: 10.2174/1568026013395605.

27. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N. et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 2011; 165 (9): 847–856. DOI: 10.1001/archpediatrics.2011.136.

28. Chuchalin A., Csiszér E., Gyurkovics K. et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr. Drugs. 2007; 9 (Suppl. 1): 21–31. DOI: 10.2165/00148581-200709001-00004.

29. Amelina E.L., Chuchalin A.G. [Inhaled tobramycin in the presence of Pseudomonas aeruginosa infection in patients with cystic fibrosis]. Pul’monologiya. 2009; (5): 120–126. DOI: 10.18093/0869-0189-2009-5-120-126 (in Russian).

30. Ratjen F., Moeller A., McKinney M.L. et al. Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study. 2018; 18 (1): 78–85. DOI: 10.1016/j.jcf.2018.04.002.

31. Mainz J.G., Schädlich K., Schien C. et al. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study. Drug Des. Devel. Ther. 2014; 8: 209–217. DOI: 10.2147/DDDT.S54064.

32. Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev. 2017; 4 (4): CD004197. DOI: 10.1002/14651858.CD004197.pub5.

33. Amelina E.L., Krasovskiy S.A. [Inhaled tobramycin in the treatment of chronic Pseudomonas aeruginosa infection in cystic fi osis]. Pul’monologiya. 2013; (4): 109–114. DOI: 10.18093/0869-0189-2013-0-4-109-114 (in Russian).

34. Atanesyan R.A., Kondrat’eva E.I., Krylova N.A. [Cystic fibrosis-related diabete]. Meditsinskiy vestnik Severnogo Kavkaza. 2020; 15 (2): 278–283. DOI: 10.14300/mnnc.2020.15068 (in Russian).

35. Public Health England. UK standards for microbiology investigations: Identification of Pseudomonas species and other non glucose fermenters. Bacteriology – Identification. 2015; (3): ID 17. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/422699/ID_17i3.pdf